FasoracetamvsNoopept

Fasoracetam upregulates GABA-B receptor (GABA-B1/GABA-B2 heterodimer) expression and function, which is unique among racetams — this receptor upregulation is potentially beneficial for restoring GABAergic sensitivity after prolonged benzodiazepine or phenibut use. It enhances group II metabotropic glutamate receptor (mGluR2/mGluR3) signaling, which modulates presynaptic glutamate release and reduces excitotoxicity. Fasoracetam increases acetylcholine release in the cerebral cortex via modulation of choline acetyltransferase activity and vesicular acetylcholine transporter function. It may also modulate the glutamatergic system through mGluR5. The combination of GABAergic (GABA-B-mediated inhibition), glutamatergic (mGluR modulation), and cholinergic enhancement provides anxiolytic effects alongside cognitive enhancement. Clinical trials focus on ADHD patients with GRM (glutamate receptor) gene variants.

Noopept modulates AMPA and NMDA receptors similarly to racetams through positive allosteric modulation. Its key distinguishing feature is upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) via activation of TrkB and TrkA receptor signaling cascades — these neurotrophins are essential for neuronal growth, survival, dendritic arborization, and synaptic plasticity. Noopept inhibits glutamate-induced excitotoxicity by reducing calcium influx through NMDA receptors and modulating the NR2B subunit. It activates the PI3K/Akt and MAPK/ERK pathways downstream of neurotrophin receptors. The active metabolite cycloprolylglycine (a cyclic dipeptide) has endogenous nootropic activity, potentially acting as a trace amine-associated receptor ligand. Neuroprotection is further mediated through antioxidant effects and mitochondrial stabilization.